PTGS2 and glioblastoma: At the molecular level, cyclooxygenase-2 (COX-2), a key mediator of inflammatory pathways, has been widely reported to be overactive in brain tumors, and may contribute to the correlation between NSAIDs use and reduced GBM tumor risk [33].